TY - JOUR T1 - Concomitant treatment with safinamide and antidepressant drugs: Safety data from real clinical practice JO - Neurología T2 - AU - Pérez-Torre,P. AU - López-Sendón,J.L. AU - Mañanes Barral,V. AU - Parees,I. AU - Fanjul-Arbós,S. AU - Monreal,E. AU - Alonso-Canovas,A. AU - Martínez Castrillo,J.C. SN - 02134853 M3 - 10.1016/j.nrl.2021.08.004 DO - 10.1016/j.nrl.2021.08.004 UR - https://www.elsevier.es/es-revista-neurologia-295-avance-resumen-concomitant-treatment-with-safinamide-antidepressant-S0213485321001298 AB - Background and purposeThe aim of this study was to assess the possible pharmacological interactions between safinamide and antidepressants, and in particular the appearance of serotonin syndrome with data from real life. MethodsWe conducted a retrospective observational study of patients with Parkinson's disease from our Movement Disorders Unit, who were under treatment with any antidepressant drug and safinamide. Specifically, symptoms suggestive of serotonin syndrome were screened for. Also, we collected time of simultaneous use, doses of levodopa and other antiparkinsonian drugs. ResultsClinical records were reviewed for the study period of September 2018 to September 2019. Seventy-eight PD patients who were treated with safinamide of which 25 (32.05%) had a concomitant treatment with an antidepressant drug, being sertraline and escitalopram the most frequent. Mean age was 80 years±8.43 and H&Y stage was 3 [2–4]. Mean dose of levodopa used was 703.75mg±233.15. Median duration of concomitant treatment with safinamide and antidepressant drug was 6 months (IQR 20.5), and over eighteen months in 5 cases. No case of serotonin syndrome was recorded, neither was any of its typical manifestations combined or in isolation. ConclusionsOur real clinical practice study suggests that concomitant use of safinamide with antidepressant drugs in PD patients seemed to be safe and well tolerated, even in the long term. However, caution is warranted, individualizing treatment regimens and monitoring the potential appearance of adverse effects. ER -